Dongsung Pharmaceutical Former CEO Accused of Embezzlement, Governance Risk Highlighted
The current CEO and inside director of Dongsung Pharmaceutical have filed a criminal complaint against the former CEO for embezzlement. The alleged amount is approximately 755.5 million KRW, representing 1.97% of equity.
This amount is an estimate based on the complaint and is not final; it may change depending on investigation results.
The incident reveals internal conflict among management, raising governance risks. Investors should be cautious about potential increased stock volatility and loss of trust.
Equity is approximately 38.34 billion KRW based on the revised 2024 year-end financial statements adjusted for subsequent capital changes.
[AI Summary]The embezzlement accusation against former management of Dongsung Pharmaceutical signals governance instability, potentially negatively affecting short-term stock price. Though the estimated amount is modest, legal uncertainties pose a risk factor.